Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Xenetic Biosciences, Inc. XBIOW NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
51/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Xenetic Biosciences, Inc. (XBIOW) is a Biotechnology company in the Healthcare sector, currently trading at $17.54. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Financials: revenue is $3M, +22.1%/yr average growth. Net income is $3M (loss), growing at +23.9%/yr. Net profit margin is -90.1% (negative). Gross margin is 100% (+1.6 pp trend).

Balance sheet: total debt is $0 against $7M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 8.32 (strong liquidity). Debt-to-assets is 0%. Total assets: $8M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future ?/100 (Fail), Income 10/100 (Fail).

XBIOW SharesGrow Score Overview

64/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — XBIOW

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
100/100
XBIOW: +22.1%/yr revenue is, +23.9%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet XBIOW: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 8.32 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
XBIOW: Gross margin is 100% (+1.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
XBIOW: Net profit margin is -90.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.02-20.5
Volume2
Avg Volume (30D)635
Market Cap$5.62M
Beta (1Y)2.30
Share Statistics
EPS (TTM)-1.58
Shares Outstanding$1.7M
IPO Date2019-07-23
Employees4
CEOJames F. Parslow
Financial Highlights & Ratios
Revenue (TTM)$2.98M
Gross Profit$2.98M
EBITDA$-2.83M
Net Income$-2.68M
Operating Income$-2.83M
Total Cash$7.88M
Net Debt$-7.88M
Total Assets$8.36M
Price / Earnings (P/E)-11.1
Price / Sales (P/S)1.89
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD

Price Chart

Track all markets on TradingView
XBIOW
Xenetic Biosciences, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.02 52WK RANGE 20.50

People Also View

VERBW
VERBW
Verb Technology Company, Inc.
$0.02
+0.00%
 ARTLW
ARTLW
Artelo Biosciences, Inc.
$0.01
+0.00%
 BCDAW
BCDAW
BioCardia, Inc.
$0.01
-3.17%
 ADILW
ADILW
Adial Pharmaceuticals, Inc. WT EXP 073123
$0.00
-57.14%
 ENTXW
ENTXW
Entera Bio Ltd. WT EXP 062723
$0.00
-60.00%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message